Download PDF
Thromb Haemost 1983; 50(04): 885-887
DOI: 10.1055/s-0038-1665335
Original Article
Schattauer GmbH Stuttgart

The Behaviour of Various Platelet Function Tests During Long-Term Prostacyclin Infusion in Patients with Peripheral Vascular Disease

H Sinzinger
The 2nd Department of Internal Medicine, University of Vienna, Austria
,
A K Horsch
1   Department of Internal Medicine, University of Heidelberg, FRG
,
K Silberbauer
The 2nd Department of Internal Medicine, University of Vienna, Austria
› Author Affiliations
Further Information

Publication History

Received 18 May 1981

Accepted 21 September 1983

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

In 20 patients with peripheral vascular disease treated with prostacyclin (5 ng/kg/min) we observed a significant activation of platelet function as measured by platelet proteins, ADP- induced aggregation platelet sensitivity and platelet count. Only the platelet survival was significantly prolonged by the treatment.

Keywords

Prostacyclin treatment - Platelet survival - Platelet proteins - ADP-induced aggregation - Platelet sensitivity antiaggregatory prostaglandins - Peripheral vascular disease
 

  • References

  • 1 Szczeklik A, Gryglewski R, Nizankowski R, Skawinski J, Gluszko P, Korbut R. Prostacyclin therapy in peripheral arterial disease. Thromb Res 1979; 19: 191-199
    PubMedGoogle Scholar
  • 2 Szczeklik A, Nizankowski R, Skawinski J, Szczeklik J, Gluszko P, Gryglewski RJ. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet 1979; 1: 1111-1114
    PubMedGoogle Scholar
  • 3 Carlson LA, Olsson AG. Intravenous prostaglandin E1 in severe peripheral vascular disease. Lancet 1976; 2: 810
    PubMedGoogle Scholar
  • 4 Machin SJ, Chamone PA, Defreyn G, Vermylen J. The effect of clinical prostacyclin infusions in advanced arterial disease on platelet function and plasma 6-keto-PGF1 alpha levels. Br J Haematol 1981; 47: 413-422
    CrossrefPubMedGoogle Scholar
  • 5 Olsson AG, Nilsson E. The effect of intravenous prostacyclin on resting pains and healing of ischemic ulcers in peripheral artery disease. Prostaglandins Med 1981; 6: 329-339
    CrossrefPubMedGoogle Scholar
  • 6 Silberbauer K, Sinzinger H, Schemthaner G, Leithner Ch, Kaliman J, Elliott M, Burghuber O. Prostacyclin infusion in men: effects on hormones and on cardiovascular system. Prostaglandins Thrombo-xanes 1980; 2: 345-349
    PubMedGoogle Scholar
  • 7 Silberbauer K, Sinzinger H, Punzengruber Ch. Long-term prostacy-clin (PGI2)-therapy in peripheral arterial disease, influence on some vascular and platelet regulation mechanisms. In: Prostaglandins in Clinical Medicine, Cardiovascular and Thrombotic Disorders. Year-book Med Publishers; 1982. pp 182-191
    Google Scholar
  • 8 Sinzinger H, Silberbauer K, Horsch AK, Gall A. Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease - a rebound phenomenon. Prostaglandins 1981; 18: 56-58
    PubMedGoogle Scholar
  • 9 Mühlhauser I, Schemthaner G, Silberbauer K, Kaliman J, Sinzinger H. Platelet specific proteins in atherosclerosis and related diseases. Artery 1981; 8: 47-55
    PubMedGoogle Scholar
  • 10 Sinzinger H, Angelberger P, Kolbe H. Influence of incubation time and temperature on indium-111-oxine uptake by human platelets. Thromb Haemostas 1981; 45: 295
    PubMedGoogle Scholar
  • 11 Siegl AM, Smith JB, Silver MJ, Nicolaou KC, Ahem D. Selective binding site for (3H)prostacyclin on platelets. J Clin Invest 1979; 63: 215-220
    CrossrefPubMedGoogle Scholar